Trials & R&D · first seen 14h ago, updated 14h ago
Precision Radiation Therapy Alone Doubles Historical Survival Rates for Inoperable Lung Cancer, Landmark Lancet Trial Finds
New York Proton Center Chief Medical Officer Dr. Charles B. Simone II Serves as Co-First Author of Groundbreaking Phase III Trial Establishing 82% Two-Year Survival Benchmark NEW YORK, Sept. 24, 2026 /PRNewswire/ -- The New York Proton Cent…
Summary from PR Newswire - Clinical Trials.